The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

English version České info

Background:
Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients.

Methods and Findings:
Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then crossed-over to the other therapy for an additional 12 weeks while continuing pre-study ART. The primary endpoint was the plasma HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly between the raltegravir-intensified (n = 25) and the placebo (n = 24) groups (median 1.2 versus 1.7 copies/mL, p = 0.55, Wilcoxon rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median −0.2 and −0.1 copies/mL, p = 0.71, Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared with the placebo group (+42 versus −44 cells/mm³, p = 0.082, Wilcoxon rank sum test), which reversed after the cross-over. This CD4 cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood.

Conclusion:
In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate reservoirs that produce residual viremia will be required to eradicate HIV-1 infection.

Trial Registration: ClinicalTrials.gov NCT00515827

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial. PLoS Med 7(8): e32767. doi:10.1371/journal.pmed.1000321
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000321

Souhrn

Zdroje

1. DornadulaG

ZhangH

VanUitertB

SternJ

LivorneseL Jr

1999 Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282 1627 1632

2. MaldarelliF

PalmerS

KingMS

WiegandA

PolisMA

2007 ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3 e46

3. PalmerS

MaldarelliF

WiegandA

BernsteinB

HannaGJ

2008 Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105 3879 3884

4. CoirasM

Lopez-HuertasMR

Perez-OlmedaM

AlcamiJ

2009 Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7 798 812

5. DinosoJB

KimSY

WiegandAM

PalmerSE

GangeSJ

2009 Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106 9403 9408

6. McMahonD

JonesJ

WiegandA

GangeS

KearneyM

2010 Short Course Raltegravir Intensification Does Not Reduce Persistent Low Level Viremia in Patients Suppressed on Combination Antiretroviral Therapy. Clin Infect Dis 50 912 919

7. SteigbigelRT

CooperDA

KumarPN

EronJE

SchechterM

2008 Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359 339 354

8. LennoxJL

DeJesusE

LazzarinA

PollardRB

MadrugaJV

2009 Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374 796 806

9. PalmerS

WiegandAP

MaldarelliF

BazmiH

MicanJM

2003 New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41 4531 4536

10. ClementLT

VinkPE

BradleyGE

1990 Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4+ cells in the human neonate. J Immunol 145 102 108

11. Rabian-HerzogC

LesageS

GluckmanE

1992 Characterization of lymphocyte subpopulations in cord blood. Bone Marrow Transplant 9 Suppl 1 64 67

12. DianzaniU

FunaroA

DiFrancoD

GarbarinoG

BragardoM

1994 Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J Immunol 153 952 959

13. HavlirDV

StrainMC

ClericiM

IgnacioC

TrabattoniD

2003 Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77 11212 11219

14. SedaghatAR

SilicianoJD

BrennanTP

WilkeCO

SilicianoRF

2007 Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog 3 e122

15. KiefferTL

FinucaneMM

NettlesRE

QuinnTC

BromanKW

2004 Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189 1452 1465

16. BuzonMJ

MassanellaM

LlibreJM

EsteveA

DahlV

2010 HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16 460 465

17. HuntPW

MartinJN

SinclairE

BredtB

HagosE

2003 T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187 1534 1543

18. GoicoecheaM

SmithDM

LiuL

MayS

TenorioAR

2006 Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 194 29 37

19. GandhiRT

SpritzlerJ

ChanE

AsmuthDM

RodriguezB

2006 Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 42 426 434

20. HsuePY

HuntPW

SchnellA

KalapusSC

HohR

2009 Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23 1059 1067

21. RichmanDD

MargolisDM

DelaneyM

GreeneWC

HazudaD

2009 The challenge of finding a cure for HIV infection. Science 323 1304 1307